The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
New Tuberculosis Therapeutics: A Growing Pipeline
Abstract
Novel chemotherapeutic drugs are needed to improve tuberculosis (TB) control, especially in the developing world. Given the magnitude of the problem and the resources available in countries that have the highest burden of disease, the present standards of care for the treatment of drug-susceptible TB, drug-resistant TB, TB/human immunodeficiency virus (HIV) coinfection, and latent TB infection are all unsatisfactory. Because no truly novel compounds for the treatment of TB have been discovered in the past 40 years, the recent enhanced activity in the research and development of new TB drugs is extremely encouraging. Seven compounds are presently in clinical development specifically for the treatment of TB. Other known antibiotic compound families are being investigated preclinically, in an attempt to identify new antimicrobial drugs with specific antituberculous activity. In addition, novel targets have been identified and are the subject of efforts to validate their potential usefulness in the treatment of TB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“[19] first described the work done by Johnson & Johnson on the research and development of TMC207 (then referred to as “R207910”), a novel diarylquinoline, for potential use in the treatment of TB.”
Background
Cited by
Pharmacological significance of triazole scaffold
Kharb, R., Sharma, P. C., & Yar, M. S. (2011) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756360903524304 · Cited by 598
Pediatric Tuberculosis: Global Overview and Challenges
Swaminathan, S., & Rekha, B. (2010) · Clinical Infectious Diseases · doi:10.1086/651490 · Cited by 377
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
Abu-Raddad, L. J., Sabatelli, L., Achterberg, J. T., Sugimoto, J. D., Longini, I. M., Dye, C., & Halloran, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901720106 · Cited by 348
Latent Tuberculosis Infection in the United States
Horsburgh, C. R., & Rubin, E. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1005750 · Cited by 311
Lilienkampf, A., Mao, J., Wan, B., Wang, Y., Franzblau, S. G., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900003c · Cited by 308
Metadata
- Authors
- Spigelman, M. K.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07
- Volume
- 196
- Issue
- s1
- Pages
- S28-S34
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2135193803
- Cited by
- 169
- References
- 1
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Tuberculosis Therapeutics: A Growing Pipeline. https://app.cochat.ai/papers/10.1086/518663
- The paper
- Spigelman, M. K. (2007). New Tuberculosis Therapeutics: A Growing Pipeline. The Journal of Infectious Diseases. https://doi.org/10.1086/518663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.